29th EAHP Congress highlights Anticholinergic burden (AB) or anticholinergic load (AL) refers to the cumulative effect of taking multiple medications with anticholinergic actions, which can lead to adverse effects,… read more.
H. Lundbeck A/S (Lundbeck) announced that recent pipeline data will be presented at the 2025 AAN Annual Meeting in San Diego, U.S. The data includes an oral presentation… read more.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of… read more.
Women with ongoing urinary incontinence could avoid invasive bladder pressure tests, as new research shows that a range of non-invasive assessments work just as well in guiding treatment…. read more.
29th EAHP Congress highlights Prescribing by hospital pharmacists is now well-established in a number of countries and there is evidence that stakeholders take a positive view of this… read more.
Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced that podium presentations will be given… read more.
29th EAHP Congress highlights Medication review, with input from pharmacy, is a national standard for post- intensive care (ICU) follow-up, set out in the Guidelines for the Provision… read more.
29th EAHP Congress highlights Cigarette smoking is a well-recognised risk factor for stroke and measures to reduce the prevalence of cigarette smoking have been implemented in many countries…. read more.
Johnson & Johnson MedTech, will feature the latest evidence demonstrating the survival benefit of Impella heart pump technology at the American College of Cardiology’s 74th Annual Scientific Sessions & Expo… read more.
Eisai Co., Ltd. announced the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment… read more.
Exelixis, Inc. announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30… read more.
Eli Lilly and Company announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
